Oberland Capital Management is pumping some new life into Biohaven, striking a unique investment deal worth up to $600 ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

A genetic signature including four genes in gastric cancer is linked to an increase in recurrence and mortality.

Pfizer pays Nearly $60M for subsidiary settlement The Justice Department alleges that from 2020 until 2022, Biohaven paid “improper remuneration, including in the form of speaker honoraria and ...

Biohaven meanwhile recorded Nurtec ODT sales of $462 million in 2021, a performance that prompted Pfizer to stump up $500 million upfront for rights to the drug outside the US last November.

Early identification of individuals at a high risk for MASLD could “profoundly transform” intervention strategies, experts ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Abu Dhabi: Abu Dhabi-backed health-care investment company M42 has taken a stake in biotech startup Juvenescence, a UK-based ...

M42 and Juvenescence will collaborate in drug discovery to develop a pipeline of innovative medicines to advance the ...